Medindia

X

FDA Priority Review for Pfizer Breast Cancer Drug

by Kathy Jones on  October 14, 2014 at 4:40 PM Cancer News   - G J E 4
An experimental breast cancer treatment will be given an accelerated review by US regulators, Pfizer has revealed. This will speed up the process for potential approval.
 FDA Priority Review for Pfizer Breast Cancer Drug
FDA Priority Review for Pfizer Breast Cancer Drug
Advertisement

The US Food and Drug Administration has granted priority review for palbociclib, which would treat certain postmenopausal women with advanced breast cancer, the US pharmaceutical giant said.

Advertisement
Under the priority review status, the FDA accelerates the review time from 10 months to a goal of six months, with a decision on approval expected by April 13, 2015, it said.

In April, Pfizer said a clinical trial had shown palbociclib slows the growth of advanced cancer.

Administered with another drug already on the market, letrozole, an aromatase inhibitor, the treatment stops cancer growth for 20 months on average, it said.

The experimental treatment is aimed at postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease.

"If approved as a first-line therapy in combination with letrozole, palbociclib will be an important new option for the thousands of women in the US who are living with metastatic breast cancer," said Garry Nicholson, president of Pfizer Oncology, in a statement.

Pfizer, which lost its global number-one status to Swiss rival Novartis, is searching for new drugs to renew growth. In recent years, patents have expired on most of its blockbusters -- drugs that have a billion dollars in annual sales -- and the company is facing stiff competition from generic versions.

Shares in Dow member Pfizer were down 0.1 percent at $29.10 in midday trade in New York.

Source: AFP
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All